Thursday 16 October, 2025
Objectives: To apply a new probabilistic PK-PD (Pharmacokinetics-Pharmacodynamics) framework to predict the probability of achieving target pharmacological effect levels of a…
Read morePoster: Methodology - New Modelling Approaches
Stochastic pharmacodynamics: Drug effects on the time to extinction of a heterogeneous tumour cell population
Thursday 16 October, 2025
Introduction: PK-PD models are often based on ordinary differential equations (ODEs) which are useful for ease of analysis but they…
Read moreModel Averaging Across Parametric and Non-Parametric Methods as an Aid for Clinical Decision Making
Thursday 16 October, 2025
Objectives: Randomized clinical trials (RCTs) are the main tool to generate patient-level data. The main analysis method of such data is…
Read moreParametric and Non-Parametric Methods in Clinical Decision Making- A Comparison of Bias and Precision using Real Clinical Data
Thursday 16 October, 2025
Objectives: Non-parametric Mixed Models for Repeated Measures (MMRM) have evolved to be the gold standard for disease progression data analysis…
Read moreA pragmatic approach to handling data below the lower limit of quantification in complex pharmacokinetic models
Thursday 16 October, 2025
Objectives: Adequate handling of data below the lower limit of quantification (BLQ) is key for parameter estimation in population pharmacokinetic (PK)…
Read moreExtending the R open-source saemix package: a new tool for parametric joint models
Thursday 16 October, 2025
Introduction: Joint modeling of longitudinal and time-to-event data has gained attention over recent years with extensive developments [1,2]. When the…
Read moreThe importance of model selection for a priori model informed precision dosing of vancomycin
Thursday 16 October, 2025
Objectives: Vancomycin is a commonly used antibiotic for gram positive infections at the Intensive Care unit. However, in 2020 only…
Read moreImpact of covariate model selection methods on covariate effects and their uncertainty in population pharmacokinetic analysis
Thursday 16 October, 2025
Introduction: Covariate analysis is a key step for drug development as it allows, notably, to adjust the dose in subpopulations…
Read moreTime-dependent random effects.
Thursday 16 October, 2025
Introduction In mixed-effect models, random effects are used to explain residual inter-individual variability. Their effect is constant over time, and…
Read moreInvestigating Components of Residual Unexplained Variability in Nonlinear Mixed-Effect Modeling
Thursday 16 October, 2025
Objectives: In nonlinear mixed-effects (NLME) modeling of pharmacokinetic (PK) and pharmacodynamic (PD) data, we refer to two levels of random effects:…
Read more